Investor Presentation is enclosed for the Results Earnings Call for quarter and half year ended September 30, 2026.

SUPRIYA LIFESCIENCE LTD. _, Creating true values that bind global lzenltlt November 6, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Presentation. Further to our Letter dated October 31, 2026, we are enclosing herewith Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2026. Kindly take the information on record. Thanking you, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE SUPRIYA LIFESCIENCE LTD. Q2 & H1 FY27 Investor Presentation Safe Harbour SUPRIYA LIFESCIENCE LTD. Thispresentationandtheaccompanyingslides(the“Presentation”),whichhavebeenpreparedbySupriyaLifescienceLimited(the“Company”),havebeenpreparedsolelyforinformation purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shallnot form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information abouttheCompany. ThisPresentationhasbeenpreparedbytheCompanybasedoninformationanddatawhichtheCompanyconsidersreliable,buttheCompanymakesnorepresentationorwarranty,express orimplied,whatsoever,andnorelianceshallbeplacedon,thetruth,accuracy,completeness,fairnessandreasonablenessofthecontentsofthisPresentation.ThisPresentationmaynot be allinclusiveand maynot containallofthe information thatyou may consider material.Any liability inrespect ofthecontentsof, or any omission from, thisPresentation isexpressly excluded CertainmattersdiscussedinthisPresentationmaycontainstatementsregardingtheCompany’smarketopportunityandbusinessprospectsthatareindividuallyandcollectivelyforward- looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technologicalimplementation,changesandadvancements,changesinrevenue,incomeorcashflows,theCompany’smarketpreferencesanditsexposuretomarketrisks,aswellasother risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Companyassumesnoobligationtoupdateanyforward-lookinginformationcontainedinthisPresentation.Anyforward-lookingstatementsandprojectionsmadebythirdpartiesincluded inthisPresentationarenotadoptedbytheCompanyandtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections. AllMapsusedinthepresentationarenottoscale.Alldata,information,andmapsareprovided"asis"withoutwarrantyoranyrepresentationofaccuracy,timelinessorcompleteness. Q2 & H1FY27 Highlights Q2 FY27 Highlights ylretrauQ ecnamrofreP lanoigeR SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT INR 2,063.0 Mn INR 454.0 Mn INR 377.8 Mn INR 292.5 Mn 3.2% YoY 37.5% YoY 44.7% YoY 42.0% YoY Business Mix Revenue Contribution –By Region 34% 36% 37% 35% Q2 FY26 21% 20% Q1 FY27 ■ Q2 FY27 3% 3% 5% 5% 3% 4% Asia Europe LATAM North America Others H1 FY27 Highlights ylretrauQ ecnamrofreP lanoigeR SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT INR 3,960.4 Mn INR 928.6 Mn INR 785.7 Mn INR 532.9 Mn 14.8% YoY 25.3% YoY 32.1% YoY 37.5% YoY Business Mix Revenue Contribution –By Region 38% 39% 40% H1 FY26 H1 FY27 4% 4% 5% Asia Europe LATAM North America Others Q2 & H1 FY27 - Y-o-Y Highlights SUPRIYA ~ LIFESCIENCE LTD. (in INRMn) Revenue EBITDA PBT PAT 3.2% YoY 14.8% YoY 37.5% YoY 25.3% YoY 44.7% YoY 32.1% YoY 42.0% YoY 37.5% YoY 1243.6 852.2 1157.3 3960.4 928.6 3449.1 726.6 683.2 785.7 504.3 532.9 1998.3 2063.0 454.0 377.8 292.5 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 EBITDA Margins PAT Margins 1,435 bps YoY 1,261 bps YoY 1,106 bps YoY 1,125 bps YoY 36.4% 36.1% 25.2% 24.7% 22.0% 23.4% 14.2% 13.5% Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Business Mix Revenue Contribution – By Therapy SUPRIYA LIFESCIENCE LTD. Performance of the Top Therapeutic Areas 12% 12% -- 6% 7% - - -- - 4% 4% 2% 2% 2% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive H1FY26 H1FY27 Profit & Loss Statement SUPRIYA LIFESCIENCE LTD. Particulars (INR Mn) Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1 FY27 H1 FY26 Y-o-Y Revenue from Operations 2,063.0 1,998.3 3.2% 1,897.5 8.7% 3,960.4 3,449.1 14.8% Cost of Goods Sold 710.6 557.3 27.5% 563.9 26.0% 1,274.5 875.0 45.6% Employee Benefits Expense 261.4 244.8 6.8% 284.9 -8.2% 546.3 471.7 15.8% Other Expenses 636.9 469.8 35.6% 574.1 10.9% 1,211.1 858.9 41.0% EBITDA 454.0 726.5 -37.5% 474.6 -4.3% 928.6 1,243.5 -25.3% EBITDA % 22.0% 36.4% -1,435 bps 25.0% -300 bps 23.4% 36.1% -1,261 bps Other Income 22.9 27.2 -15.9% 26.5 -13.4% 49.4 54.0 -8.5% Depreciation and Amortisation Expense 94.6 66.4 42.5% 89.4 5.8% 184.0 130.9 40.6% EBIT 382.4 687.3 -44.4% 411.7 -7.1% 794.0 1,166.6 -31.9% Finance Costs 4.6 t 4.1 10.3% 3.7 22.5% 8.3 9.3 -10.3% PBT 377.8 683.2 -44.7% 407.9 -7.4% 785.7 1,157.3 -32.1% Total Tax Expense 85.3 t 178.9 -52.3% 167.5 -49.1% 252.8 305.1 -17.2% Profit for the year 292.5 504.3 -42.0% 240.4 21.7% 532.9 852.2 -37.5% PAT % 14.2% 25.2% -1,106 bps 12.7% 151 bps 13.5% 24.7% -1,125 bps EPS (INR) 5.04 6.30 2.99 6.62 10.59 Balance Sheet SUPRIYA LIFESCIENCE LTD. INR Mn Assets Mar 26 Sep 26 Equity and Liabilities Mar 26 Sep 26 Non-current assets Equity (i) Property, plant and equipment 6,833 7,286 (i) Equity share capital 161 161 (ii) Right to Use Asset 45 48 (ii) Other equity 11,816 12,265 (iii)Capital Work in progress 355 71 Total Equity 11,977 12,426 (iv) Intangible Assets 13 12 Non-current liabilities (v) Financial Assets (i) Financial Liabilities -Investments 985 1,066 -Borrowings - - -Loans and Advances - - -Lease Liabilities 52 55 (vi) Other Non-Current Assets 16 28 -Other financial liabilities - - Total Non-current assets 8,248 8,512 (ii) Provisions 19 15 (iii) Deferred tax Liabilities 312 416 Current assets Total Non-Current Liabilities 383 487 (i) Inventories 1,596 2,652 Current liabilities (ii) Financial Assets (i) Financial liabilities -Trade receivables 2,194 1,256 -Borrowings - - -Cash and cash equivalents 375 410 -Lease Liabilities 2 3 -Bank balances other than above 413 349 -Trade payables 1,108 1,071 -Other financial Assets - - -Other financial liabilities 20 107 -Loans and Advances 6 5 (iii) Provisions 17 9 (iii) Other current assets 738 1,033 (ii) Other current liabilities 62 114 Total Current Assets 5,323 5,705 Total Current Liabilities 1,210 1,304 TOTAL ASSETS 13,571 14,217 TOTAL EQUITY AND LIABILITIES 13,571 14,217 Company Overview Business Overview SUPRIYA LIFESCIENCE LTD. Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics& Anesthetics 40+ 120+ 35,000 932 APIs Count [Showing first 8,000 characters — download PDF for full document]